Informações de Bristol-Myers Squibb Co | Histórico, dados financeiros e desempenho de mercado

Informações de Bristol-Myers Squibb Co Empresa

Informações da empresa

Código da empresaBMY

Nome da EmpresaBristol-Myers Squibb Co

Data de listagemJul 05, 1929

Fundado em1933

CEODr. Christopher S. (Chris) Boerner, Ph.D.

Funcionários34100

Tipo de TítulosOrdinary Share

Fim do ano fiscalJul 05

EndereçoRoute 206 And Province Line Road

CidadePRINCETON

Bolsa de ValoresNYSE Consolidated

PaísUnited States of America

Código postal08543

Telefone16092524621

Sitehttps://www.bms.com/in

Código da empresaBMY

Data de listagemJul 05, 1929

Fundado em1933

Executivos da Empresa

Nome

Nome/Posição

Posição

Ações Detidas

Variação

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

5.33K

+65.41%

Ms. Cari Gallman

Executive Vice President, Corporate Affairs, Member of the Leadership Team

5.01K

+137.97%

Mr. Robert Plenge, M.D., Ph.D.

Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team

--

Mr. Peter J. (Pete) Arduini

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações Detidas

Variação

Ms. Sandra Leung

Executive Vice President, General Counsel, Member of the Leadership Team

448.10K

+6.18%

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

104.62K

+1.95%

Mr. Samit Hirawat, M.D.

Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team

63.93K

+2.94%

Dr. Julia A. Haller, M.D.

Independent Director

13.61K

--

Mr. Phil Holzer

Senior Vice President, Controller

11.76K

-5.62%

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

6.65K

+1.16K%

Detalhamento da Receita

Moeda: USDTempo de atualização: qua, 5 de mar

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por EmpresaUSD

Nome

Receita

Proporção

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

Por RegiãoUSD

Nome

Receita

Proporção

United States

34.10B

70.61%

International

13.19B

27.32%

other

996.00M

2.06%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Eliquis

13.33B

27.60%

Opdivo

9.30B

19.26%

Revlimid

5.77B

11.95%

Orencia

3.68B

7.62%

Pomalyst/Imnovid

3.54B

7.33%

Other

12.66B

26.21%

Acionista

Tempo de atualização: sex, 21 de fev

Estatísticas do Acionista

Tipo

Estatísticas do Acionista

Acionista

Proporção

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

Estatísticas do Acionista

Acionista

Proporção

The Vanguard Group, Inc.

9.31%

BlackRock Institutional Trust Company, N.A.

4.78%

State Street Global Advisors (US)

4.68%

JP Morgan Asset Management

3.10%

Charles Schwab Investment Management, Inc.

2.97%

Other

75.13%

Tipo

Acionista

Proporção

Investment Advisor

36.81%

Investment Advisor/Hedge Fund

32.60%

Research Firm

2.76%

Pension Fund

2.50%

Bank and Trust

2.25%

Sovereign Wealth Fund

1.85%

Hedge Fund

1.70%

Holding Company

0.23%

Insurance Company

0.16%

Other

19.10%

Instituição Participações

Tempo de atualização: dom, 19 de jan

Período do Relatório

Nº de instituições

Ações detidas

Proporção

Variação

2025Q1

4136

1.64B

81.10%

+16.36M

2024Q4

4261

1.64B

81.14%

+17.04M

2024Q3

4116

1.59B

78.69%

-22.72M

2024Q2

4105

1.58B

78.35%

-83.11M

2024Q1

4118

1.64B

80.97%

+13.32M

2023Q4

4115

1.60B

78.83%

-46.38M

2023Q3

4042

1.62B

77.83%

-55.49M

2023Q2

4082

1.65B

78.77%

-34.93M

2023Q1

4110

1.65B

78.74%

-34.09M

2022Q4

4105

1.65B

77.92%

-72.60M

Ver Mais

Atividade dos Acionistas

Nome

Ações detidas

Proporção

Variação

Chg %

Data

The Vanguard Group, Inc.

189.01M

9.31%

+1.40M

+0.74%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

97.01M

4.78%

-7.45M

-7.13%

Dec 31, 2024

State Street Global Advisors (US)

95.14M

4.68%

+2.24M

+2.42%

Dec 31, 2024

JP Morgan Asset Management

63.09M

3.1%

+12.35M

+24.34%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

60.30M

2.97%

-729.92K

-1.19%

Dec 31, 2024

Capital International Investors

45.86M

2.26%

+3.21M

+7.54%

Dec 31, 2024

Geode Capital Management, L.L.C.

44.39M

2.18%

+1.18M

+2.74%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

35.17M

1.73%

+2.58M

+7.91%

Dec 31, 2024

Columbia Threadneedle Investments (US)

28.49M

1.4%

+12.26M

+75.54%

Dec 31, 2024

Fidelity Management & Research Company LLC

27.55M

1.35%

-9.07M

-24.77%

Dec 31, 2024

Ver Mais

ETFs Relacionados

Tempo de atualização: há 15 horas

Nome

Proporção

First Trust NASDAQ Pharmaceuticals ETF

8.03%

Invesco S&P Ultra Dividend Revenue ETF

6.78%

NYLI Healthy Hearts ETF

4.96%

iShares U.S. Pharmaceuticals ETF

4.8%

Invesco Pharmaceuticals ETF

4.79%

VanEck Morningstar Wide Moat Value ETF

4.58%

VanEck Pharmaceutical ETF

4.37%

Schwab U.S. Dividend Equity ETF

4.3%

Cullen Enhanced Equity Income ETF

3.79%

SPDR S&P Pharmaceuticals ETF

3.67%

Ver Mais

First Trust NASDAQ Pharmaceuticals ETF

Proporção8.03%

Invesco S&P Ultra Dividend Revenue ETF

Proporção6.78%

NYLI Healthy Hearts ETF

Proporção4.96%

iShares U.S. Pharmaceuticals ETF

Proporção4.8%

Invesco Pharmaceuticals ETF

Proporção4.79%

VanEck Morningstar Wide Moat Value ETF

Proporção4.58%

VanEck Pharmaceutical ETF

Proporção4.37%

Schwab U.S. Dividend Equity ETF

Proporção4.3%

Cullen Enhanced Equity Income ETF

Proporção3.79%

SPDR S&P Pharmaceuticals ETF

Proporção3.67%

Dividendo

Um total de 22.71B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro das ações

Data de pagamento

Data de ex-dividendo

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Jun 14, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option

Jul 07, 2023

Aug 01, 2023

Jul 06, 2023

Mar 03, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023

Apr 10, 2023

May 01, 2023

Apr 06, 2023

Dec 08, 2022

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023

Jan 06, 2023

Feb 01, 2023

Jan 05, 2023

Sep 14, 2022

BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022

Oct 07, 2022

Nov 01, 2022

Oct 06, 2022

Ver Mais

Desdobramento de Ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

Bristol-Myers Squibb Co

60.150USD

Bristol-Myers Squibb Co

60.150

Visão Geral

Empresa